Trial Search Results

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.

PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: asparaginase
  • Drug: cyclophosphamide
  • Drug: cytarabine
  • Drug: daunorubicin hydrochloride
  • Drug: dexamethasone
  • Drug: doxorubicin hydrochloride
  • Drug: leucovorin calcium
  • Drug: mercaptopurine
  • Drug: methotrexate
  • Drug: prednisone
  • Drug: thioguanine
  • Drug: vincristine sulfate
  • Radiation: radiation therapy

Phase:

Phase 3

Eligibility


DISEASE CHARACTERISTICS:

   - Newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic
   lymphoma*

      - Less than 25% tumor cells in the bone marrow

      - Previously untreated (prior intrathecal cytarabine allowed if protocol therapy
      begins within 72 hours)

      - Stage III or IV disease

   - NOTE: *Localized lymphoblastic lymphoma is closed to accrual as of 10/2005

PATIENT CHARACTERISTICS:

Age:

   - 1 to 30

Performance status:

   - Not specified

Life expectancy:

   - Not specified

Hematopoietic:

   - Not specified

Hepatic:

   - Not specified

Renal:

   - Not specified

Cardiovascular:

   - Adequate cardiac function

PRIOR CONCURRENT THERAPY:

Biologic therapy:

   - Not specified

Chemotherapy:

   - See Disease Characteristics

Endocrine therapy:

   - Emergency steroid therapy (if required) must be started within 72 hours prior to
   protocol therapy

Radiotherapy:

   - Emergency radiotherapy (if required) must be started within 72 hours prior to protocol
   therapy

Surgery:

   - Not specified

Other:

   - No other prior therapy except for emergency treatment of airway obstruction and/or
   superior vena cava syndrome

Ages Eligible for Study

1 Year - 30 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting